See the DrugPatentWatch profile for remicade
Does Remicade (infliximab) treat inflammatory bowel disease?
Yes. Remicade (infliximab), a tumor necrosis factor (TNF) blocker, is used to treat several forms of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. It helps reduce intestinal inflammation and can bring symptoms under control and keep the disease from flaring in some patients.
Which IBD types is Remicade used for?
Remicade is used in people with:
- Crohn’s disease
- Ulcerative colitis
(These are the main IBD indications associated with infliximab/Remicade.)
How does Remicade work in IBD?
Remicade targets TNF-alpha, an inflammatory signal involved in IBD. By blocking TNF-alpha, it can lower inflammatory activity in the gut, which helps improve symptoms such as diarrhea, abdominal pain, rectal bleeding (for ulcerative colitis), and overall disease activity.
How quickly can symptoms improve?
Some people notice symptom improvement within weeks after starting treatment, while others may take longer depending on disease severity, prior treatments, and whether they respond to infliximab. Clinicians also monitor how well treatment controls inflammation over time, not just symptoms.
What happens if Remicade doesn’t help or stops working?
If Remicade doesn’t work, or it loses effect over time, doctors may adjust the dosing schedule, add or switch other medications, or move to a different biologic or treatment approach. One reason loss of response can occur is the development of antibodies against infliximab, which can reduce drug levels and effectiveness.
Risks and side effects patients ask about
Common concerns include infusion-related reactions and infection risk (because TNF blockade can affect the immune system). Patients typically get screened for infections such as tuberculosis and monitored during therapy. For detailed safety guidance, clinicians rely on prescribing information and patient-specific risk factors.
Who makes Remicade and are there alternatives?
Remicade is a branded infliximab product. Infliximab is also available as biosimilars in many markets, which can offer alternative options for patients and payers depending on availability and treatment history.
If you share which IBD you have (Crohn’s vs ulcerative colitis), how severe it is, and what you’ve tried before, I can outline the typical decision paths doctors use for whether Remicade is a good fit.